#Novamind inc trial#

For example, Canada’s Special Access program “permits health care practitioners to request access to drugs that have shown promise in clinical trials or been approved in other countries, but that have not yet been authorized for sale in Canada.”Īdditionally, its 56(1) exemptions allow individuals with end-of-life anxiety or depression to get psilocybin on a case-by-case basis. While Canada does not have any approved therapeutic products containing psilocybin, the government does have exemption programs. Psilocybin is a hallucinogenic compound found in certain types of mushrooms. Yet, recently, Canada has led the way in psilocybin assisted treatment.

#Novamind inc trial#

This trial is important because it could be used to support regulatory approval for the medication for the FDA. Since then, the Multidisciplinary Association for the Psychedelic Studies worked with the FDA on a Phase 3 MDMA-Assisted Therapy PTSD. has a strong history of psychedelic research.įor example, five years ago the FDA granted Breakthrough Therapy Designation to use MDMA to treat Post Traumatic Stress Disorder. Novamind has partnerships with five larger insurers for ketamine assisted psychotherapy. The Novamind acquisition also brings with it insurer agreements. market, which we plan on expanding upon.” “ has given us a very strong footing and step into the U.S. “We usually say it’s kind of like a ‘one plus one equals five’ in regards to what it’s done for the organization,” Nyquvest said.